Objective:To evaluate the use of TACE combined with radiotherapy in patients with primary hepatocel-lular carcinoma with portal vein tumor thrombus on the survival of patients. Methods:84 cases of primary liver cancer patients with portal vein thrombosis from January 2011 to January 2016,according to the methods of treatment,were divided into experimental and control groups,the control group only received TACE treatment,and the experimental group,with the acceptance of three-dimensional conformal radiotherapy based on control. Curative effect,survival,the adverse reactions and quality of life during treatment Karnofsky score situation of the two groups were compared. Re-sults:After appropriate treatment,the total effective rate of the experimental group was 55. 81%(24/43),significantly higher than 34. 15%(14/41)in control group,and the difference was statistically significant(P﹤0. 05). In experi-mental group,1 year survival rate 53. 49%,2-year survival rate 32. 56%,the average survival time(14. 87 ± 2. 12) months,were significantly better than the control group,and the difference was statistically significant(P﹤0. 05). Bone marrow suppression,liver damage,the incidence of gastrointestinal reactions and radiological hepatitis differ-ences in two groups of patients during the treatment were no statistically significant(P﹥0. 05). In the two groups af-ter the end of treatment or symptomatic treatment remission,no serious adverse reactions. After treatment,the experi-mental group Karnofsky score was lower and increased in the control group,the difference was statistically significant ( P﹤0. 05). After 3 months of treatment Karnofsky score increased significantly in the experimental group which sig-nificantly better than the control group,with statistically significant(P﹤0. 05). Conclusion:TACE combined with ra-diotherapy for primary hepatocellular carcinoma with portal vein tumor thrombus can significantly improve the clinical efficacy and prolong survival time and improve quality of life,and no serious adverse reactions and safe.%目的：探讨TACE联合放疗治疗原发性肝癌合并门静脉癌栓对患者生存情况的影响。方法：选择2011年1月-2016年1月在我院接受治疗的84例原发性肝癌合并门静脉癌栓患者，按照治疗方法的不同分为实验组与对照组，对照组仅接受TACE治疗，实验组则在对照组的基础上接受三维适形放疗，比较两组患者的近期疗效、生存状况、治疗期间不良反应及生存质量Karnofsky评分情况。结果：经过相应的治疗后实验组的总有效率为55.81%（24/43），显著高于对照组34.15%（14/41），差异具有统计学意义（P﹤0.05）。实验组1年生存率为53.49%，2年生存率为32.56%，平均生存期为（14.87±2.12）月，均显著优于对照组，差异具有统计学意义（ P﹤0.05）。两组患者治疗期间骨髓抑制、肝功能损伤、消化道反应及放射性肝炎等不良反应的发生率比较差异无统计学意义（ P﹥0.05）。两组患者不良反应在治疗结束后或对症处理后缓解，均未出现严重不良反应。治疗后实验组Karnofsky评分降低，对照组Karnofsky评分有所升高，差异具有统计学意义（ P﹤0.05），治疗后3个月实验组Karnofsky评分升高明显，显著优于对照组，差异具有统计学意义（ P﹤0.05）。结论：TACE联合放疗治疗原发性肝癌合并门静脉癌栓可显著提高临床疗效，延长生存时间，改善生存质量，且无严重不良反应，安全性高。
展开▼
